Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
77 hedge funds and large institutions have $195M invested in Adaptimmune Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 23 reducing their positions, and 15 closing their positions.
213% more call options, than puts
Call options by funds: $219K | Put options by funds: $70K
0.54% more ownership
Funds ownership: 70.28% → 70.82% (+0.54%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 80 → 77 (-3)
15% less capital invested
Capital invested by funds: $229M → $195M (-$34.2M)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
30% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$11.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$803K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$515K |
| 4 |
Barclays
London,
United Kingdom
|
+$434K |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$2.28M |
| 2 |
Renaissance Technologies
New York
|
-$772K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$579K |
| 4 |
Rafferty Asset Management
New York
|
-$548K |
| 5 |
Two Sigma Investments
New York
|
-$544K |
ADAP Hedge Fund Activity: Q2 2022 in Review
77 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2022, worth a combined $195M — down 15% from $229M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ADAP and 12 opened new positions — a net loss of 3 holders — while 23 trimmed existing stakes and 16 added.
The largest buyer was PFM Health Sciences, adding an estimated $11.6M. The largest seller was Millennium Management, cutting an estimated $2.28M.
- 77 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2022, down from 80 in Q1 2022.
- Funds reported $195M of Adaptimmune Therapeutics stock for Q2 2022, down 15% quarter-over-quarter.
- 12 funds opened new Adaptimmune Therapeutics positions in Q2 2022 and 15 closed out, a net change of -3 holders.
- The largest Adaptimmune Therapeutics buyer in Q2 2022 was PFM Health Sciences, an estimated $11.6M added.
- The largest Adaptimmune Therapeutics seller in Q2 2022 was Millennium Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q2 2022.